Cell therapy for Parkinson's disease: NouvNeu001 trial
Treatments studied
Part of Brain & nervous system clinical trials.
This trial tests a new cell therapy, NouvNeu001, for people with Parkinson's disease who have had symptoms for at least 4 years and are having trouble with their current medications. The goal is to see if this treatment is safe and can improve motor symptoms that are not well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old.
- You have had Parkinson's disease for 4 years or more.
- Your motor symptoms are not well controlled by current Parkinson's medications.
- You are able to undergo brain surgery and have tests like MRI and CT scans.
- You agree not to have any other brain surgery (like deep brain stimulation) for 2 years.
- You have not had cell or gene therapy in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell treatment for people with Parkinson's disease. It's for those whose symptoms affect daily life and who still respond to levodopa but find it less effective over time.
This trial tests whether transplanting specially grown cells (DopaCell) into the brain can safely help people with moderate Parkinson's disease whose symptoms aren't well controlled by medication. The cells are intended to produce dopamine, the chemical that Parkinson's affects.
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
This Phase 1 study tests whether an “autologous” (from your own body) iNSC-DAP stem-cell treatment is safe and may help symptoms in Parkinson’s disease. It is designed mainly to check safety, while also watching for signs of improvement.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.